Citius Oncology (CTOR) Return on Capital Employed (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Return on Capital Employed of 93.55% for Q1 2026, down 2553.0% year-over-year from 3.81% in Q1 2025, and down 153.92% quarter-over-quarter from 36.84% in Q4 2025.
Citius Oncology (CTOR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Return on Capital Employed for 4 consecutive years, with 93.55% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2553.0% year-over-year to 93.55%; the TTM figure through Mar 2026 stood at 93.55% (down 2553.0% YoY), while the FY2025 annual figure was 54.5%, down 957.0% from the prior year.
- Return on Capital Employed retreated to 93.55% in Q1 2026 per CTOR's latest filing, from 36.84% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.75% in Q4 2023 and bottomed at 93.55% in Q1 2026.
- Historically, Return on Capital Employed has averaged 50.31% across 4 years, with a median of 50.23% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 2022 bps in 2025 and fell as far as 5801 bps in 2025.
- Citius Oncology's Return on Capital Employed stood at 9.75% in 2023, then tumbled by 485 bps to 57.06% in 2024, then jumped by 35 bps to 36.84% in 2025, then plunged by 154 bps to 93.55% in 2026.
- Business Quant data shows CTOR's Return on Capital Employed at 93.55% in Q1 2026, 36.84% in Q4 2025, and 50.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Citius Oncology | 76.60 Mn | 76.60 Mn | 1.00 Mn | -99.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.55% |
| Dec 31, 2025 | -36.84% |
| Sep 30, 2025 | -50.23% |
| Jun 30, 2025 | -84.79% |
| Mar 31, 2025 | -68.02% |
| Dec 31, 2024 | -57.06% |
| Jun 30, 2024 | -42.51% |
| Mar 31, 2024 | -10.01% |
| Dec 31, 2023 | -9.75% |